Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How sacral nerve stimulation neuromodulation works.

Wendy W Leng1, Michael B Chancellor

  • 1Department of Urology, University of Pittsburgh School of Medicine, 3471 Fifth Avenue, Suite #700, Pittsburgh, PA 15213, USA. lengww@upmc.edu

The Urologic Clinics of North America
|February 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genitourinary phenotype of COVID: a personal perspective.

International urology and nephrology·2026
Same author

Senescence-Driven Inflammation and Immune Dynamics in the Progression of Radiation Cystitis.

Cells·2026
Same author

Safety and Efficacy of LP-10 Liposomal Tacrolimus in Oral Lichen Planus: A Multicenter Phase 2 Trial.

Dermatology and therapy·2025
Same author

Advancing Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Diagnosis: A Comparative Analysis of Machine Learning Methodologies.

Diagnostics (Basel, Switzerland)·2024
Same author

Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal Inflammatory Diseases.

Cureus·2024
Same author

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial.

Neurourology and urodynamics·2024
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Sacral neuromodulation (SNS) treats lower urinary tract dysfunction by inhibiting sensory processing in the spinal cord. This safe, minimally invasive technique offers hope for diverse urinary issues.

Area of Science:

  • Urology
  • Neuroscience
  • Physiology

Background:

  • Lower urinary tract dysfunction (LUTS) encompasses diverse storage and emptying abnormalities.
  • Current treatments for LUTS have limitations, necessitating novel therapeutic approaches.
  • Sacral neuromodulation (SNS) is an established, minimally invasive urologic technique.

Purpose of the Study:

  • To elucidate the underlying neurophysiologic mechanisms of Sacral Neuromodulation (SNS) for lower urinary tract dysfunction (LUTS).
  • To demonstrate how SNS leverages spinal cord sensory processing for therapeutic benefit.
  • To highlight the potential of SNS in treating a wide spectrum of LUTS.

Main Methods:

  • The study proposes a neurophysiologic model for SNS action.
  • Analysis of afferent signaling pathways within the sacral spinal cord.

Related Experiment Videos

  • Review of existing clinical data on SNS efficacy for LUTS.

    • Main Results:

    • SNS action is primarily based on somatic afferent inhibition of spinal sensory processing.
    • Pudendal afferent signaling is a key neural pathway targeted by SNS.
    • SNS can modulate both voiding reflexes and suppress hyperactive voiding pathways.

    Conclusions:

    • SNS offers a unified mechanism for treating diverse LUTS by modulating spinal afferent pathways.
    • The technique is safe, minimally invasive, and effective for various lower urinary tract conditions.
    • SNS presents a promising therapeutic option for patients with refractory LUTS.